Statements (74)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Aurelia_Bioscience
|
| gptkbp:ceo |
gptkb:Franz-Werner_Haas
|
| gptkbp:clinical_trial |
gptkb:m_RNA_cancer_vaccine
gptkb:Cure_Vac's_m_RNA_cancer_vaccine gptkb:drug Phase 2 C V8102 C Vn Co V Phase 2b/3 C V7202 C Vn Co V Phase 1 C Vn Co V Phase 3 C Vn Co V booster dose study C Vn Co V booster study C Vn Co V combination study C Vn Co V cost-effectiveness study C Vn Co V effectiveness study C Vn Co V efficacy monitoring study C Vn Co V efficacy study C Vn Co V health economics study C Vn Co V health outcomes study C Vn Co V health service utilization study C Vn Co V health technology assessment study C Vn Co V immunogenicity study C Vn Co V long-term efficacy study C Vn Co V long-term follow-up study C Vn Co V long-term immunogenicity study C Vn Co V long-term safety study C Vn Co V observational study C Vn Co V patient-reported outcomes study C Vn Co V pediatric study C Vn Co V phase 4 study C Vn Co V post-marketing study C Vn Co V quality of life study C Vn Co V real-world effectiveness study C Vn Co V real-world evidence study C Vn Co V safety and immunogenicity study C Vn Co V safety monitoring study C Vn Co V safety study C Vn Co V variant study |
| gptkbp:collaborations |
gptkb:Eli_Lilly
gptkb:Harvard_University gptkb:University_of_Pennsylvania gptkb:MIT |
| gptkbp:employees |
~300 (2021)
|
| gptkbp:focus |
m RNA technology
|
| gptkbp:founded |
gptkb:2000
|
| gptkbp:founder |
gptkb:Ingmar_Hoerr
|
| gptkbp:headquarters |
gptkb:Tübingen,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cure Vac Inc.
|
| gptkbp:invention |
m RNA technology patents
|
| gptkbp:investment |
gptkb:Bill_&_Melinda_Gates_Foundation
|
| gptkbp:is_vulnerable_to |
gptkb:vaccine
|
| gptkbp:partnership |
gptkb:GSK
gptkb:temple gptkb:Bayer_AG gptkb:Pfizer gptkb:Moderna |
| gptkbp:products |
C Vn Co V
|
| gptkbp:receives_funding_from |
$1.3 billion (2020 IPO)
|
| gptkbp:research |
gptkb:Dr._Klaus_Schaefer
|
| gptkbp:research_areas |
oncology
rare diseases autoimmune diseases infectious diseases |
| gptkbp:revenue |
€ 20.5 million (2020)
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:symbol |
CVAC
|
| gptkbp:technology |
messenger RNA
vaccine development RNA-based therapeutics |
| gptkbp:website |
www.curevac.com
|
| gptkbp:bfsParent |
gptkb:Cure_Vac_AG
|
| gptkbp:bfsLayer |
4
|